MiMedx Group, Inc. is a placental biologics company. The Company is engaged in developing and distributing placental tissue allografts with patent-protected, processes for multiple sectors of healthcare. Its product portfolio categories include Wound Care Products, and Surgical and Other Products. Its Wound Care Products include EPIFIX, EPICORD and EPIEFFECT, which are all marketed for external use, such as in advanced wound care applications. Its Surgical and Other product offering includes AMNIOFIX, AMNIOCORD and AMNIOEFFECT, which are positioned for use in a variety of applications and surgical settings, including lower extremity repair, plastic surgery, vascular surgery and multiple orthopedic repairs and reconstructions. The Company's platform technologies include tissue allografts derived from the human placental membrane, tissue allografts derived from the human umbilical cord, and a particulate extracellular matrix derived from the human placental disc.
BörsenkürzelMDXG
Name des UnternehmensMiMedx Group Inc
IPO-datumAug 20, 2007
CEOMr. Joseph H. (Joe) Capper
Anzahl der mitarbeiter837
WertpapierartOrdinary Share
GeschäftsjahresendeAug 20
Addresse1775 W Oak Commons Court, Ne
StadtMARIETTA
BörseNASDAQ Capital Market Consolidated
LandUnited States of America
Postleitzahl30062
Telefon17706519100
Websitehttps://mimedx.com/
BörsenkürzelMDXG
IPO-datumAug 20, 2007
CEOMr. Joseph H. (Joe) Capper
In den vergangenen 5 Jahren wurden insgesamt
0.00
USD an Dividenden ausgeschüttet.

Keine Daten